5-MeO-DMT vs Ibogaine
A side-by-side research comparison of 5-MeO-DMT and Ibogaine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | 5-MeO-DMT | Ibogaine |
|---|---|---|
| Full name | 5-Methoxy-N,N-dimethyltryptamine | Ibogaine (from Tabernanthe iboga) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (research compound) |
| Mechanism | Strongly activates serotonin 5-HT1A and 5-HT2A receptors, producing rapid and intense changes in consciousness. | Acts on multiple systems at once, including serotonin and opioid receptors, NMDA receptors and nicotinic receptors. Its active metabolite noribogaine is thought to drive much of the lasting anti-addiction effect. |
| Molecular weight | 218.30 g/mol | 310.43 g/mol |
| Half-life | Short (minutes) | ~4-7 hours (ibogaine); noribogaine much longer |
| Bioavailability | Inhaled/injected | Oral |
| Typical dose | Low milligram range in clinical studies | Weight-based, given in specialized clinics |
| Frequency | One to a few supervised sessions | Usually a single session |
| Route | Inhalation or injection in research settings | Oral, under medical and cardiac monitoring |
5-MeO-DMT reported benefits
- Studied for treatment-resistant depression
- Short duration suits clinical use
- Explored for anxiety
- Rapid onset of effects
Ibogaine reported benefits
- Studied for opioid use disorder
- Can reduce withdrawal symptoms quickly
- May lower cravings after a single session
- Investigated for traumatic brain injury (with magnesium) in veterans
Related comparisons
Research and educational reference only. Not medical advice.